UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 18, 2003
-------------
CYTOGEN CORPORATION
-------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
650 College Road East, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(609) 750-8200
------------------------------------------
(Registrant's telephone number,
including area code)
--------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Required FD Disclosure.
On June 18, 2003, Advanced Magnetics, Inc. ("Advanced Magnetics") and Cytogen
Corporation ("Cytogen") announced in a press release the publication of clinical
data in the New England Journal of Medicine showing that magnetic resonance
imaging with Combidex(R), Advanced Magnetic's investigational iron oxide
nanoparticle used to aid in the diagnosis of lymph node disease, allows for the
noninvasive assessment of lymph nodes in patients with prostate cancer. Cytogen
has a license with Advanced Magnetics for exclusive marketing rights to
Combidex(R) in the United States.
Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference. The foregoing description of such press release is qualified in
its entirety by reference to such document.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release dated June 18, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cytogen Corporation
By: /s/ Michael D. Becker
----------------------------------------
Michael D. Becker,
President and Chief Executive Officer
Date: July 3, 2003